66th ASH Annual Meeting: 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes

Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Elderly, Clinical Research, Health outcomes research, Supportive Care, Diseases, Treatment Considerations, Real-world evidence, Lymphoid Malignancies, Adverse Events, Myeloid Malignancies, Study Population, Human

Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

Moderators:

Rory M. Shallis, MD, Yale School of Medicine - Yale Cancer Center and Daisuke Tomizawa, MD, PhD, National Center for Child Health and Development

Disclosures:

Tomizawa: Nihon Servier: Honoraria; Otsuka Pharmaceutical: Honoraria; Miyarisan Pharmaceutical Co., Ltd.: Honoraria; Astellas Pharma Inc.: Honoraria; Taiho Pharma: Honoraria; Abbvie Inc.: Honoraria; Amgen Inc.: Honoraria; Pfizer Japan Inc.: Honoraria; Nippon Shinyaku Co., Ltd.: Honoraria; Novartis: Honoraria; Meiji Seika Pharma: Consultancy, Honoraria.

9:30 AM

445

Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience

Leora Boussi, MD¹, Hannah Burton²^*, Andriy Derkach, PhD³^*, David Nemirovsky³^*, Jenna Ciervo, PharmD⁴^*, Martin S. Tallman, MD⁵, Eytan M. Stein, MD⁶ and Sheng Cai, MD, PhD⁴

¹Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Drexel University College of Medicine, Philadelphia, PA
³Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Memorial Sloan Kettering Cancer Center, New York, NY
⁵Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Highland Park, IL
⁶Department of Medicine; Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY

9:45 AM

446

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Ian M. Bouligny, MD¹, Hagop M. Kantarjian, MD¹, Musa Yilmaz, MD¹^*, Naval Daver, MD², Gautam Borthakur, MD³, Courtney D. DiNardo, MD, MSc¹, Guillermo Montalban-Bravo, MD¹, Nicholas J. Short, MD¹, Yesid Alvarado Valero, MD¹, Nitin Jain, MD¹, Naveen Pemmaraju, MD¹, Danielle Hammond, MD¹, Kelly S. Chien, MD⁴, Koichi Takahashi, MD, PhD⁵, Ghayas C. Issa, MD¹, Hussein A. Abbas, MD, PhD¹, Elias Jabbour, MD¹, Guillermo Garcia-Manero, MD¹, Farhad Ravandi, MBBS⁶ and Tapan M. Kadia, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²MD Anderson Cancer Center, Houston, TX
³Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, MD Anderson, Houston, TX
⁵Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

10:00 AM

447

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Samuel J. Yates, MD, MSc¹, Julian J. Weiss, MD²^*, Abigail Sneider, MD³^*, Emily Geramita, MD, PhD⁴, Guru Subramanian Guru Murthy, MBBS⁵, Talha Badar, MD⁶, Annie Im, MD⁷, Chenyu Lin, MD⁸, Wei Cheng, PhD⁹^*, Eric S. Winer, MD¹⁰, Yasmin Abaza, MD¹¹, Mark R. Litzow, MD¹², Ehab L. Atallah, MD⁵, Alok Swaroop, MD, PhD¹³^*, Anand Ashwin Patel, MD¹ and Rory M. Shallis, MD¹⁴

¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
²Department of Internal Medicine, Duke University Medical Center, Durham, NC
³University of Chicago Pritzker School of Medicine, Chicago, IL
⁴UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
⁵Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
⁶Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
⁷UPMC Hillman Cancer Center, Univ. of Pittsburgh Cancer Institute, Pittsburgh, PA
⁸Duke University Cancer Institute, Durham, NC
⁹Department of Biostatistics, Yale School of Public Health, New Haven, CT
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹Northwestern University, Chicago, IL
¹²Division of Hematology, Mayo Clinic, Rochester, MN
¹³Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
¹⁴Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, Killingworth, CT

10:15 AM

448

Frailty and Long-Term Survival Among Older Adults with Blood Cancers

Clark DuMontier, MD, MPH^1,2,3^*, Angel Cronin, MS⁴^*, Tammy T Hshieh, MD, MPH^2,3^*, Ameya Sanyal, BA²^*, Michelle Fredericks, MPH²^*, Nicholas Groblewski, BA²^*, Lee Mozessohn, MD⁵, Daniel J DeAngelo, MD, PhD^2,3, Richard M Stone, MD^2,3, Robert J. Soiffer, MD^2,3, Jane A Driver, MD, MPH^1,3^* and Gregory A Abel, MD, MPH^3,6

¹Veterans Affairs Boston Healthcare System, Boston, MA
²Dana-Farber Cancer Institute, Boston, MA
³Brigham and Women's Hospital, Boston, MA
⁴Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁵Sunnybrook Health Sciences Centre, Toronto, ON, Canada
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

10:30 AM

449

FRAIL-HRU-AML: Impact of Frailty Assessment on Health Resource Utilization in Acute Myeloid Leukemia Patients: A Population-Based Study from Ontario, Canada

Gopila Gupta¹^*, Sho Podolsky²^*, Ning Liu, PhD³^*, Matthew C. Cheung, MD, MSc⁴ and Aniket Bankar, MD, MBBS, MSc, DM¹

¹Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
²Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada
³ICES, Toronto, ON, Canada
⁴Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

10:45 AM

450

A Retrospective Analysis of Intensive Chemotherapy Vs. Venetoclax/Hypomethylating Agents for Patients Aged 60-75 with Favorable-Risk, NPM1-Mutated AML

Andrew Zale, MD¹^*, Alexander J. Ambinder, MD, MPH² and Venkata Preetam Sandeep Kaduluri, MBBS, MPH³^*

¹Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
³Sidney Kimmel Comprehensive Cancer Center/Division of Hematological Malignancies and Bone Marrow Transplantation, Johns Hopkins Hospital, Baltimore, MD

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

615.O2.3 615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes